particularly active, responsible for approximately 80% of the total roughly $1 trillion since 2010. Impressively, their M&A activities have significantly ramped up in the past five years, with an average annual M&A investment of $6 billion since 2019. This marks a substantial increase, doubling from the previous annual average of $3 billion. Since 2010, four prominent pharmaceutical companies have collectively invested over $60 billion in public M&A (approximately $8O billion today, accounting for inflation). This significant investment accounts for 4o% of the total transaction value in the sector. During this period, each of these M&A leaders completed a significant transformative acquisition. Noteworthy Takeda's purchase of Shire and Pfizer's merger with Seagen. in today's value). These firms generally target companies with more-streamlined portfolios, often focusing on those with an average of one to five clinical assets, rather than a broad and